{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:53:23Z","timestamp":1790639603597,"version":"4.1.0"},"reference-count":90,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Aquaporin-4-Antik\u00f6rper-positive Neuromyelitis-optica-Spektrum-Erkrankung (engl. NMOSD) und die Myelin-Oligodendrozyten-Glykoprotein-Antik\u00f6rper-assoziierte Erkrankung (engl. MOGAD) sind\n\t\t\t\t\tAutoimmunerkrankungen des zentralen Nervensystems. Typische Erstmanifestationen sind bei Erwachsenen Optikusneuritis und Myelitis. Eine Beteiligung auch von Hirn und Hirnstamm, sp\u00e4testens im\n\t\t\t\t\tweiteren Verlauf, ist h\u00e4ufig. W\u00e4hrend die NMOSD nahezu immer schubf\u00f6rmig verl\u00e4uft, nimmt die MOGAD gelegentlich einen monophasischen Verlauf. Die Differenzialdiagnostik ist anspruchsvoll und\n\t\t\t\t\tst\u00fctzt sich auf u.\u200aa. auf radiologische und serologische Befunde. Die Abgrenzung von der h\u00e4ufigeren neuroinflammatorischen Erkrankung, Multiple Sklerose (MS), ist von erheblicher Bedeutung,\n\t\t\t\t\tda sich Behandlung und langfristige Prognose von NMOSD, MOGAD und MS wesentlich unterscheiden. Die vielf\u00e4ltigen Symptome und die umfangreiche Diagnostik machen eine enge Zusammenarbeit\n\t\t\t\t\tzwischen Ophthalmologie, Neurologie und Radiologie erforderlich. Dieser Artikel gibt einen \u00dcberblick \u00fcber typische MRT-Befunde und die serologische Antik\u00f6rperdiagnostik bei NMOSD und MOGAD.\n\t\t\t\t\tZwei illustrative Fallberichte aus der \u00e4rztlichen Praxis erg\u00e4nzen die Darstellung.<\/jats:p>","DOI":"10.1055\/a-1918-1824","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T23:37:05Z","timestamp":1669073825000},"page":"1315-1324","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostik der Neuromyelitis-optica-Spektrum-Erkrankung (NMOSD) und der MOG-Antik\u00f6rper-assoziierten Erkrankung (MOGAD)"],"prefix":"10.1055","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-9079","authenticated-orcid":false,"given":"Darius","family":"Mewes","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin & Max-Delbr\u00fcck-Centrum f\u00fcr molekulare Medizin Berlin, Berlin, Deutschland"},{"name":"NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Biomedical Innovation Academy, Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kuchling","sequence":"additional","affiliation":[{"name":"NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Biomedical Innovation Academy, Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Klinik f\u00fcr Neurologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schindler","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin & Max-Delbr\u00fcck-Centrum f\u00fcr molekulare Medizin Berlin, Berlin, Deutschland"},{"name":"NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Klinik f\u00fcr Neurologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abdelrahim Ahmed","family":"Khalil","sequence":"additional","affiliation":[{"name":"Centrum f\u00fcr Schlaganfallforschung, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Abteilung Neurologie, Max-Planck-Institut f\u00fcr Kognitions- und Neurowissenschaften, Leipzig, Deutschland"},{"name":"Mind Brain Body Institute, Berlin School of Mind and Brain, Humboldt-Universit\u00e4t zu Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[{"name":"AG Molekulare Neuroimmunologie, Neurologische Klinik, Universit\u00e4t Heidelberg, Heidelberg, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin & Max-Delbr\u00fcck-Centrum f\u00fcr molekulare Medizin Berlin, Berlin, Deutschland"},{"name":"NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Klinik f\u00fcr Neurologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Chien","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin & Max-Delbr\u00fcck-Centrum f\u00fcr molekulare Medizin Berlin, Berlin, Deutschland"},{"name":"NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"},{"name":"Klinik f\u00fcr Psychiatrie und Psychotherapie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"S Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"S Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","article-title":"[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing]","volume":"89","author":"S Jarius","year":"2018","journal-title":"Nervenarzt"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with\n\t\t\t\t\tAQP4-IgG, and origin","volume":"13","author":"S Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and\n\t\t\t\t\tlong-term outcome","volume":"13","author":"S Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement \u2013 frequency, presentation and outcome","volume":"13","author":"S Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive\n\t\t\t\t\tpatients","volume":"13","author":"F Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"R Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"S Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-019-1594-1","article-title":"The history of neuromyelitis optica. Part 2: \u201cSpinal amaurosis\u201d, or how it all began","volume":"16","author":"S Jarius","year":"2019","journal-title":"J Neuroinflammation"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"S S Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1034","DOI":"10.1212\/NXI.0000000000001034","article-title":"Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder","volume":"8","author":"J Li","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/NXI.0000000000001027","article-title":"Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases","volume":"8","author":"K Schanda","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis","volume":"9","author":"N Borisow","year":"2018","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice","volume":"10","author":"M Royston","year":"2021","journal-title":"Neurol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/WNL.0000000000200052","article-title":"Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody\u2013Associated Disease: CHANCENMO Study","volume":"98","author":"M W H\u00fcmmert","year":"2022","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14728214.2020.1803828","article-title":"Emerging drugs for the treatment of neuromyelitis optica","volume":"25","author":"A Duchow","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"J P Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"D M Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"P Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"M Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"A J Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"M P Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics","volume":"14","author":"R Geraldes","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211014389","article-title":"A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course","volume":"14","author":"J M Solomon","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"A T Toosy","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"S Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol","volume":"10","author":"A Petzold","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"F Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"I Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"J J Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"S Ramanathan","year":"2016","journal-title":"Mult Scler"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders","volume":"216","author":"M Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e1068","DOI":"10.1212\/NXI.0000000000001068","article-title":"Retinal Optical Coherence Tomography in Neuromyelitis Optica","volume":"8","author":"F C Oertel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"F C Oertel","year":"2018","journal-title":"EPMA J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3892\/etm.2016.3474","article-title":"3D-DIR for early differential diagnostic and prognostic evaluation of NMO","volume":"12","author":"Y Wang","year":"2016","journal-title":"Exp Ther Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1007\/s00330-020-06859-w","article-title":"Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders","volume":"30","author":"V Juenger","year":"2020","journal-title":"Eur Radiol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1212\/NXI.0000000000001135","article-title":"Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss","volume":"9","author":"M Denis","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1177\/1352458513519838","article-title":"Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders","volume":"20","author":"F von Glehn","year":"2014","journal-title":"Mult Scler"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/1352458519849511","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study","volume":"26","author":"J Ciron","year":"2020","journal-title":"Mult Scler"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e1912732","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs. Aquaporin-4 Antibody Disease","volume":"2","author":"R Mariano","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/NXI.0000000000000985","article-title":"Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients","volume":"8","author":"I Ayzenberg","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies","volume":"11","author":"S Asseyer","year":"2020","journal-title":"Front Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318796684","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"S Asseyer","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"M Filippi","year":"2016","journal-title":"The Lancet Neurology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody","volume":"76","author":"D Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"C Chien","year":"2019","journal-title":"Mult Scler"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1352458515591069","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging","volume":"22","author":"Y Pekcevik","year":"2016","journal-title":"Mult Scler"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00115-021-01092-2","article-title":"Differenzialdiagnostik autoimmun-entz\u00fcndlicher R\u00fcckenmarkserkrankungen","volume":"92","author":"F C Oertel","year":"2021","journal-title":"Nervenarzt"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"E P Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1212\/NXI.0000000000001167","article-title":"Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?","volume":"9","author":"Z Poullet","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1212\/WNL.0b013e318297ef07","article-title":"Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient","volume":"81","author":"N Asgari","year":"2013","journal-title":"Neurology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.2361040450","article-title":"Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging","volume":"236","author":"J JG Geurts","year":"2005","journal-title":"Radiology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","article-title":"Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis","volume":"120","author":"F Barkhof","year":"1997","journal-title":"Brain"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"L Matthews","year":"2013","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaneurol.2019.2478","article-title":"Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis","volume":"76","author":"T Sinnecker","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13167-015-0038-y","article-title":"Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management","volume":"6","author":"T Sinnecker","year":"2015","journal-title":"EPMA J"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e3124","DOI":"10.1212\/WNL.0000000000010847","article-title":"Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder","volume":"95","author":"M Y Lee","year":"2020","journal-title":"Neurology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"M Jury\u0144czyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1352458513506953","article-title":"The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders","volume":"20","author":"S Y Huh","year":"2014","journal-title":"Mult Scler"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaneurol.2015.0248","article-title":"Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder","volume":"72","author":"S Kremer","year":"2015","journal-title":"JAMA Neurol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"M Nakamura","year":"2009","journal-title":"Mult Scler"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"S Salama","year":"2020","journal-title":"Mult Scler"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","article-title":"Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome","volume":"266","author":"A Budhram","year":"2019","journal-title":"J Neurol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cei.13641","article-title":"Clinical and neuroimaging findings in MOGAD\u2013MRI and OCT","volume":"206","author":"F Bartels","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"S Jarius","year":"2013","journal-title":"Brain Pathol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/ceo.13863","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review","volume":"49","author":"J Sharma","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/B978-0-12-800100-4.00006-4","article-title":"Immunopathogenesis of neuromyelitis optica","volume":"121","author":"M Levy","year":"2014","journal-title":"Adv Immunol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"T Misu","year":"2007","journal-title":"Brain"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1055\/a-1219-7907","article-title":"[Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment]","volume":"237","author":"B Wildemann","year":"2020","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"S Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"S Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","article-title":"Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen","volume":"291","author":"S Jarius","year":"2010","journal-title":"J Neurol Sci"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"S Jarius","year":"2010","journal-title":"J Neurol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2014.1581","article-title":"Seroprevalence of Aquaporin-4\u2013IgG in a Northern California Population Representative Cohort of Multiple Sclerosis","volume":"71","author":"S J Pittock","year":"2014","journal-title":"JAMA Neurol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"C Trebst","year":"2014","journal-title":"J Neurol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"S Jarius","year":"2008","journal-title":"Brain"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1212\/NXI.0000000000000759","article-title":"Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?","volume":"7","author":"M Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"J Kitley","year":"2012","journal-title":"Neurology"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"P Peschl","year":"2017","journal-title":"J Neuroinflammation"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"S Saadoun","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"S Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"S Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00115-021-01106-z","article-title":"[Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. A brief review]","volume":"92","author":"S Jarius","year":"2021","journal-title":"Nervenarzt"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"S Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?","volume":"30","author":"M Reindl","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"M Gastaldi","year":"2020","journal-title":"J Neurol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"D H Whittam","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders","volume":"9","author":"M Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"D M Wingerchuk","year":"2006","journal-title":"Neurology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1918-1824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:34:42Z","timestamp":1676028882000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1918-1824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":90,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1918-1824","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}